ConductScience.org, home

Paper40720060

Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.

de Castro C and 14 others. Adv Ther, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan. Papers, record 40720060. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40720060

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.
PubMed
Journal
Adv Ther
PubMed
Year
2025
PubMed
Publication types
Journal Article, Clinical Trial, Phase III, Multicenter Study
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.73, provisional
iCite
Revised in PubMed
2025-09-12
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1de Castro CCarloshttps://orcid.org/0000-0002-4485-6025
2Kelly RJRichard J
3Griffin MMorag
4Patriquin CJChristopher J
5Mulherin BBrian
6Höchsmann BBritta
7Selvaratnam VVeena
8Wong RSMRaymond Siu Ming
9Hillmen PPeter
10Horneff RRegina
11Uchendu UOUchendu O
12Zhang YYiwei
13Surova EElena
14Szamosi JJohan
15de Latour RPRegis Peffault

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hemoglobinuria, ParoxysmalMajor topic
Antibodies, Monoclonal, HumanizedMajor topic
Complement C3Major topic
Complement Inactivating AgentsMajor topic
Humans
Male
Female
Middle Aged
Adult
Treatment Outcome
Aged
Hemoglobins
Complement C5
Bilirubin
Reticulocyte Count

Source PubMed

Download CSV of topics

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT03500549Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Derived from the trialYesClinicalTrials.gov
NCT03531255Pegcetacoplan Long Term Safety and Efficacy Extension StudyDerived from the trialYesClinicalTrials.gov
NCT04085601A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNHDerived from the trialYesClinicalTrials.gov

Download CSV of trials

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138071133Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape.Blood Rev2024https://conductscience.org/library/papers/38071133PubMed
236532073Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan.Front Immunol2022https://conductscience.org/library/papers/36532073PubMed
311900238Fatigue in cancer patients compared with fatigue in the general United States population.Cancer2002https://conductscience.org/library/papers/11900238PubMed
423610373Thrombosis in paroxysmal nocturnal hemoglobinuria.Blood2013https://conductscience.org/library/papers/23610373PubMed
537707673Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report.Adv Ther2023https://conductscience.org/library/papers/37707673PubMed
639734592Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators.Ther Adv Hematol2024https://conductscience.org/library/papers/39734592PubMed
733512400How I treat paroxysmal nocturnal hemoglobinuria.Blood2021https://conductscience.org/library/papers/33512400PubMed
819179465Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.Blood2009https://conductscience.org/library/papers/19179465PubMed
97566002Natural history of paroxysmal nocturnal hemoglobinuria.N Engl J Med1995https://conductscience.org/library/papers/7566002PubMed
1030442279General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale.Value Health2018https://conductscience.org/library/papers/30442279PubMed
1137994576Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health-related quality of life and productivity.Eur J Haematol2024https://conductscience.org/library/papers/37994576PubMed
1236732204Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.Blood Rev2023https://conductscience.org/library/papers/36732204PubMed
1336848639Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.Blood Adv2023https://conductscience.org/library/papers/36848639PubMed
1438812989Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings.Res Pract Thromb Haemost2024https://conductscience.org/library/papers/38812989PubMed
1534386754Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019.EClinicalMedicine2021https://conductscience.org/library/papers/34386754PubMed
1620145265Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.Haematologica2010https://conductscience.org/library/papers/20145265PubMed
1735830642Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition.N Engl J Med2022https://conductscience.org/library/papers/35830642PubMed
1838142401Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.Blood2024https://conductscience.org/library/papers/38142401PubMed
1938315872Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH.Blood Adv2024https://conductscience.org/library/papers/38315872PubMed
2038348608Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.Am J Hematol2024https://conductscience.org/library/papers/38348608PubMed

See all 28 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42636034Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria.J Comp Eff Res2026https://conductscience.org/library/papers/42636034PubMed
42319133Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles.Eur J Immunol2026https://conductscience.org/library/papers/42319133PubMed
42185224
Pegcetacoplan Delivers Real-World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real-World Clinical and Patient-Reported Outcomes.
Eur J Haematol2026https://conductscience.org/library/papers/42185224PubMed
41596089Redox Regulation of Complement Pathway Activation in Aging and Related Diseases.Antioxidants (Basel)2025https://conductscience.org/library/papers/41596089PubMed
41348037The varieties of therapeutic experience: navigating treatment options for patients with PNH.Hematology Am Soc Hematol Educ Program2025https://conductscience.org/library/papers/41348037PubMed

Download CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
PEGCETACOPLANCHEMBL4298211Derived from the trial3https://conductscience.org/library/drugs/CHEMBL4298211

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40720060

GET https://conductscience.org/api/papers/v1/40720060/references?page=2